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Abstract. Androgen-independent prostate carcinoma is
characterized by a high proliferation rate and by a strong
metastatic behavior. We have previously shown that GnRH
agonists exert a direct and specific inhibitory action on the
proliferation of androgen-independent prostate cancer cells
(DU 145). These compounds mainly act by interfering with the
mitogenic activity of growth factors, such as the insulin-like
growth factor-I (IGF-I). The present experiments were
performed to clarify whether GnRH agonists might also
affect the migratory and the invasive behavior of androgen-
independent prostate cancer cells and to define their mech-
anism of action. First we showed that the GnRH agonist
Leuprolide reduces the migration of DU 145 cells towards a
chemoattractant and their ability to invade a reconstituted
basement membrane. Experiments were then performed to
clarify whether the GnRH agonist might act by interfering
with the pro-metastatic activity of IGF-I. We found that, in
androgen-independent prostate cancer cells, Leuprolide: a)
interferes with the IGF-I system (receptor protein expression
and tyrosine-phosphorylation); b) abrogates the IGF-I-induced
phosphorylation of Akt (a kinase previously shown by us to
mediate the pro-metastatic activity of IGF-I in prostate cancer
cells); c) counteracts the migration and the invasive activity
of the cells stimulated by IGF-I; d) abolishes the effects of
IGF-I on cell morphology, on actin cytoskeleton organization
and on ·vß3 integrin expression/cellular localization. These
data indicate that GnRH agonists, in addition to their well
known antiproliferative effect, can also exert a significant
inhibitory activity on the migratory and invasive behavior of
androgen-independent prostate cancer cells, expressing the
GnRH receptor. GnRH agonists act by interfering with the
pro-metastatic activity of the growth factor IGF-I.
Introduction
Prostate cancer is the most frequent malignancy and the second
leading cause of male cancer deaths in Western countries (1).
In its earlier stages, the disease is androgen-dependent and,
therefore, androgen-deprivation therapy represents the first-
line treatment for prostate cancer patients (2). After an initial
phase of remission, prostate carcinoma almost inevitably
progresses towards a condition of hormone-resistance, which is
characterized by a high proliferation rate, by a strong metastatic
behavior, and by the refractoriness to classical chemotherapy
(3). Growth factors, either locally produced or exogenous, the
insulin-like growth factor-I (IGF-I) in particular, have been
widely shown to be deeply involved in the growth and
progression of prostate carcinoma (4-6). Prostate cancer cells
produce IGF-I, express IGF-I receptors (IGF-IR) and exhibit
a significant responsiveness to the mitogenic activity of IGF-I
in vitro (7-10), while IGF-IR inhibition by means of antisense
RNA reduces prostate cancer cell proliferation (11). In in vivo
studies (performed in SCID mice), the progression of
androgen-dependent prostate cancer xenografts (derived
from the LAPC-9 and LNCaP cell lines) towards a phase of
androgen-independence is associated with increased levels of
both IGF-I and IGF-IR (12); similarly, prostate IGF-I mRNA
expression was found to increase during prostate cancer
progression in TRAMP mice and to be elevated in the
accompanying metastases (13). Finally, high serum levels of
IGF-I were reported to be associated with an increased risk
of prostate cancer in men (14-16); the level of expression of
IGF-IR, which is up-regulated in primary prostate cancer,
seems to persist in the metastatic disease (17,18). Recently,
IGF-I has been reported to increase both the invasive (19) and
the migratory (20) behavior of androgen-independent prostate
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cancer cells, indicating that this growth factor might regulate
not only the growth but also the progression of prostate cancer
towards the highly aggressive metastatic phase.
Gonadotropin-releasing hormone (GnRH) agonists, through
the blockade of the pituitary-testicular axis and the consequent
suppression of testosterone secretion, represent the most widely
utilized therapy for hormone-responsive prostate carcinoma
(2). Moreover, in our (21,22) and in other (23) laboratories it
has been demonstrated that GnRH agonists can exert a
specific antiproliferative effect on androgen-dependent prostate
cancer cells, suggesting that, when utilized for treating patients,
these drugs might also exert an additional and more direct
antitumor activity. Expression of GnRH receptors and
significant antiproliferative effects of GnRH analogs have
also been reported for androgen-independent prostate cancer
cells, both in vitro (24) and in vivo when inoculated into nude
mice (23,25,26). These observations suggest that GnRH
agonists might exert an anti-tumorigenic action also on
hormone-refractory prostate cancer and, therefore, implicate
that their clinical application might also be extended to this
stage of pathology. In the present study, we investigated
whether GnRH agonists might affect the migratory and the
invasive properties of androgen-independent prostate cancer
cells, in particular of DU 145 cells, and whether they might
interfere with the pro-metastatic activity of IGF-I; the
molecular mechanisms of this interaction were clarified.
Materials and methods
Materials. The GnRH agonist Leuprolide (D-Leu6-Des-Gly10-
GnRH-N-ethylamide) acetate was kindly provided by Takeda
(Japan). Human recombinant IGF-I was purchased from
Peprotech EC Ltd. (London, UK); mouse anti-·vß3 anti-
body was obtained from Chemicon (Temecula, CA) while
vitronectin was from Sigma Chemical Co. (St. Louis, MO).
Cell cultures. The cell line DU 145, derived from a brain meta-
stasis of a human hormone-unresponsive prostate carcinoma,
and the PC3 cell line, derived from bone metastasis of a
human hormone-independent prostate cancer, were obtained
from American Type Culture Collection (Rockville, MD).
DU 145 cells (passages 60-74) and PC3 cells (passages 20-35)
were routinely grown in RPMI-1640 medium supplemented
with fetal bovine serum (FBS; Gibco, Paisley, Scotland, UK)
(5% for DU 145 and 10% for PC3 cells), glutamine (1 mM)
and antibiotics (100 IU/ml penicillin G sodium and 100 μg/ml
streptomycin sulphate). Cells were incubated at 37˚C in a
humidified atmosphere of 5% CO2/95% air.
Cell proliferation studies. Cell growth studies were performed
on exponentially growing cells. DU 145 cells were plated at a
density of 500 cells/cm2 in 100-mm dishes; they were allowed
to attach and to start growing for 3 days. The media were
then changed and cells were treated daily with Leuprolide
(10-11-10-6 M, 500 μl), as previously described for different
GnRH agonists (24). After 7 days of treatment, cells were
harvested and counted by hemocytometer. Each experimental
group consisted of 6 replicates and each experiment was
repeated 3 times. The data were analyzed according to the
Bonferroni's test after one-way ANOVA.
Western blot analysis of IGF-IR, IGF-IR phosphorylation
and Akt phosphorylation
IGF-IR protein expression. IGF-IR expression was
analyzed by Western blotting. DU 154 cells were seeded at a
density of 5x105 cells in 100-mm dishes in RPMI-1640
medium with 5% FBS and treated with Leuprolide (10-6 M) for
24 h. At the end of the treatment, cells were harvested using
RIPA buffer (0.05 M Tris.HCl pH 7.7, 0.15 M NaCl, 0.8%
SDS, 10 mM EDTA, 100 μM NaVO4, 50 mM NaF, 0.3 mM
PMSF, 5 mM iodoacetic acid) containing leupeptin and
aprotinin (1 μg/ml). The extracts were centrifuged to remove
insoluble material. Protein contents were determined using
the BCA method. Equal amounts of proteins (30 μg) for each
experimental sample were resuspended in sample buffer (0.5 M
Tris-HCl pH 6.8, glycerol 20%, SDS 10%, 2ß-mercaptoethanol
0.2%, blue bromophenol 0.05%) and heated at 95˚C for 5 min.
Following separation by 7.5% SDS-PAGE, proteins were
electrotransferred to nitrocellulose, and membranes were
then blocked with 3% BSA. Filters were incubated with the
IGF-IR antibody (1.5 μg/ml, 2 h at room temperature)
(Chemicon). After repeated washing, membranes were
incubated with horseradish peroxidase-conjugated secondary
antibodies. Proteins were finally visualized by chemilumin-
escence (SuperSignal Chemiluminescence Detection System,
Pierce Biotechnology Inc., Rockford, IL). A monoclonal
antibody against actin (actin, Ab-1 kit, Oncogene Research
Products, San Diego, CA) was used to control for equal
loading.
Tyrosine phosphorylation of IGF-IR. To study the possible
interaction of GnRH agonists with the IGF-I-induced tyrosine
phosphorylation of IGF-IR, DU 145 cells were plated at a
density of 5x105 cells in 100-mm dishes in RPMI-1640
medium supplemented with 5% FBS. After 3 days, cells were
refed with serum-free medium for 24 h and then pretreated,
for 1 or 2 h, with Leuprolide (10-6 M) before IGF-I stimulation
(10 nM, 3 min), as previously described (10). At the end of
the treatment, the experimental medium was removed, the
cell layer was rinsed with PBS and cells were then harvested
in 1 ml RIPA buffer on ice for 10 min. Cell lysates were
centrifuged at 15,000 x g for 20 min; supernatants were
immunoprecipitated with 2 μg/20 μl of the monoclonal
antibody IGF-IR· (Santa Cruz Biotechnology Inc., Santa Cruz,
CA), raised against IGF-IR, for 15 min in the presence of 10 μl
rabbit anti-mouse IgG. Protein Sepharose (75 μl) was added
at room temperature for 30 min, and samples were then
centrifuged at 4,000 x g for 5 min. Precipitated proteins were
electrophoresed by SDS-PAGE on a 7.5% polyacrylamide
gel and blotted onto a nitrocellulose filter. Filters were
incubated with antiphosphotyrosine monoclonal antibody
(IgG2bk, Upstate Biotechnology, Lake Placid, NY) (1 μg/ml)
for 1 h at room temperature and then with an anti-mouse IgG
at the final concentration of 1:5000. Antibody bound to
phosphotyrosine was detected by chemiluminescence.
Akt phosphorylation. DU 145 cells were seeded at a density
of 5x105 cells in 10-mm dishes in RPMI-1640 medium with
5% FBS. After 3 days, the medium was changed to serum-
free medium and cells were treated with Leuprolide (10-6 M)
for 1 or 2 h, either in the absence or in the presence of IGF-I
(10 nM) during the last 30 min of incubation. At the end of
the treatment, the cell layer was rinsed with PBS and cells
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were harvested using RIPA buffer. Western blot analysis was
performed as described above. The following primary anti-
bodies were used at a dilution of 1:100 (overnight at 4˚C):
anti-phospho-Akt (SC 7985-R; Santa Cruz Biotechnology) or
anti-Akt (SC 5298, Santa Cruz Biotechnology). All these
experiments were repeated 3 times.
Cell migration assays. Cell migration was analyzed by means
of haptotactic assays, using a 48-well Boyden's chamber
(Neuroprobe, Cabin John, MD) in which the lower surface of
the membrane had been precoated with vitronectin (5 μg/
100 μl). After each specific treatment, prostate cancer cells
were harvested, resuspended in 5% FBS additioned medium
plus treatments, and cell suspensions (105 cells/50 μl, in culture
media plus the specific treatment) were placed in the open-
bottom wells of the upper compartment of the chamber. Each
pair of wells were separated by polyvinylpyrrolidone-free poly-
carbonate porous membrane (8 μm pores) precoated with
vitronectin. The lower compartment of the chambers was
filled with serum-free medium. The chambers were then kept
for 4 h in the cell culture incubator. After that, the cells
migrated through the pores and adhered to the underside
of the membrane were fixed, stained (Diff-Quick kit, DADE,
Dudingen, CH) and mounted onto glass slides. For quantitative
analysis, six random objective fields of stained cells were
counted for each well (8 wells/experimental group) and the
mean number of migrating cells/mm2 was calculated.
Preliminary experiments were performed to evaluate the
effects of the GnRH agonist on the migratory behavior of
prostate cancer cells. To this purpose, subconfluent DU 145
cells, grown in serum-supplemented medium, were treated
for 4 days with Leuprolide (10-6 M) and harvested at the end
of the treatment. Haptotactic assays were then performed as
described above.
Subsequent experiments were performed to evaluate
whether the GnRH agonist might interfere with the pro-
migratory activity of IGF-I. DU 145 cells, cultured in the
absence of serum, were treated with Leuprolide (10-6 M) alone
for 4 days, with IGF-I (10 nM) alone for 24 h, or with
Leuprolide (4 days) in the presence of IGF-I during the last
24 h. Haptotactic assays were then performed. To confirm
the results obtained, similar experiments were performed on
PC3 cells.
In each of these assays, triplicate wells were performed,
and the assay was repeated 3 times. The data from all migration
assays were analyzed according to the Bonferroni's test after
one-way ANOVA.
Invasion (Matrigel) assays. Preliminary experiments were
performed to verify whether GnRH agonists might affect the
invasive properties of androgen-independent prostate cancer
cells. To this purpose, subconfluent DU 145 cells were
collected by trypsinization, resuspended in complete medium
and seeded in 20 μl (150,000 cells/drop) on the lid of a
culture dish. The lid was then placed on a dish filled with 2
ml of culture medium and incubated at 37˚C for 48 h.
Matrigel solution (80 μl, 2.7 mg/ml) was pipetted onto the
bottom of wells of a 24-well culture dish, and left to set at
37˚C. Cell aggregates were gently pipetted and transferred
over the cushion and then overlaid with additional 20 μl
Matrigel. The aggregates into Matrigel were covered with
400 μl RPMI-1640 supplemented with 5% FBS, in the
presence or in the absence of Leuprolide (10-6 M). Aggregates
in Matrigel covered with RPMI-1640 without FBS supple-
mentation served as negative controls. The aggregates were
then observed daily under a light microscope and at 4 and 9
days phase-contrast pictures of the aggregates were taken. The
experiments were repeated 3 times.
To clarify whether Leuprolide might interfere with the pro-
invasive properties of IGF-I, the Matrigel invasion chamber
was utilized, as previously described (27). This method was
utilized because it allows a quantitative evaluation of the
effect and, therefore, a statistical analysis of the results.
Transwell plates equipped with 23.1-mm polycarbonate
inserts of pore size 8.0 μm (Becton Dickinson, Bedford, MA)
were precoated with 0.8 mg/insert solubilized tissue
basement membrane (Matrigel) and allowed to dry in a sterile
hood overnight. DU 145 cells, cultured in the absence of
serum, were treated with Leuprolide (10-6 M) alone for 4 days,
with IGF-I (10 nM) alone for 24 h, or with Leuprolide (4 days)
in the presence of IGF-I during the last 24 h. Cells were then
harvested by trypsinization, resuspended in their basal medium
plus treatment, and seeded into the upper compartment of the
invasion chamber at 350,000 cells/well in a volume of 2 ml;
the lower compartment of the chamber was filled with 20%
FBS-supplemented medium (3 ml). Cells were allowed to
invade the Matrigel preparation and to migrate for 72 h at
37˚C. At the end of the assay, non-invasive cells were removed
from the upper surface of the membrane with a cotton swab.
Cells that had invaded the Matrigel coating were fixed,
stained (Diff-Quick kit, DADE), and counted. In each of these
assays, triplicate wells were performed, and the assay was
repeated 3 times. The data were analyzed according to the
Bonferroni's test after one-way ANOVA.
Scanning electron microscopy. For scanning electron micro-
scopy, DU 145 cells (3x104 cells/coverslip) were seeded on
vitronectin-coated coverslips and incubated in serum-free
medium with IGF-I (10 nM) and Leuprolide (10-6 M), either
alone or in combination, for 30 min. Cells were then washed
in PBS for 10 min and fixed in 2% glutaraldehyde in 0.1 M
cacodylate buffer and then washed in the same buffer. Cover-
slips were postfixed in aqueous 4% OsO4 for 20 min, washed
in distilled water for 10 min, immersed in aqueous 1% tannic
acid for 20 min and washed in distilled water for 10 min. This
procedure was repeated 3 times at room temperature. Cells
were dehydrated in alcohol, immersed in isoamylacetate and
dried by the critical-point method. Coverslips were sputter-
coated with gold/palladium and observed under a scanning
electron microscope (Autoscan Siemens). This experiment was
repeated 2 times for 2 different preparations.
Cytoskeletal organization. The effects of IGF-I and the GnRH
agonist, either alone or in combination, on the pattern of
actin and tubulin distribution were analyzed by immuno-
fluorescence staining. DU 145 cells were grown on 22-mm
glass coverslips and treated, in serum-free conditions, with
IGF-I (10 nM) and Leuprolide (10-6 M), either alone or in
combination, for 30 min. Cells were then fixed with 3%
paraformaldehyde in 2% sucrose-PBS for 15 min and
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permeabilized with 0.5% Hepes/Triton buffer (20 mM Hepes,
300 mM sucrose, 50 mM NaCl, 3 mM MgCl2, 0.5% Triton
X-100) for 1 min. For actin visualization cells were stained
with tetramethylrhodamine B isothiocyanate (TRITC)-
phalloidin (0.4 μg/ml) (Sigma Chemical Co.). For tubulin
organization, fixed cells were incubated with an unlabeled
monoclonal anti-tubulin primary antibody (1:500) (clone
DM 1A, Sigma Chemical Co.), followed by TRITC-conjugated
goat anti-mouse secondary antibody (Alexa Fluor 488,
Molecular Probes, Eugene, OR). Labeled cells were examined
under a Zeiss Axiovert 200 microscope with a 63x/1.4
objective lens. Images were acquired using the Metavue
program. Each staining was repeated 3 times for 3 different
preparations for each group.
Expression of integrin ·vß3. The effects of IGF-I and
Leuprolide, either alone or in combination, on the expression
of the ·vß3 integrin dimer were evaluated by immuno-
fluorescence as well as by biotinylation and immunopre-
cipitation. This integrin was selected since its expression has
been demonstrated to correlate with the aggressiveness and
invasiveness of prostate cancer cells (28). The integrin ·vß3
binds to different proteins of the extracellular matrix,
including vitronectin, utilized for the migration assays in the
present study (29).
Immunofluorescence analysis. DU 145 cells (3x104 cells/
coverslip) were grown on 13-mm glass coverslips and treated,
in serum-free conditions, with IGF-I (10 nM) and Leuprolide
(10-6 M), either alone or in combination, for 30 min. Cells
were then fixed with paraformaldehyde (as described above)
and incubated with an unlabeled anti-·vß3 primary antibody
(Chemicon), followed by fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse secondary antibody (Molecular
Probes). Labeled cells were examined as described above for
cytoskeletal proteins. Each staining was repeated 3 times for
3 different preparations for each group.
Biotinylation and immunoprecipitation. These experiments
were performed as previously described (30). DU 145 cells,
grown in serum-free medium, were treated with IGF-I (10 nM)
and Leuprolide (10-6 M), either alone or in combination, for
24 h. The cells were then washed 5 times with Hank's buffer
and incubated with 2 ml of Hank's buffer supplemented with
500 mg/ml sulfoccinimidyl hexanoate-conjugated biotin (NHS-
LC-Biotin, Pierce Biotechnology Inc.) to label cell surface
proteins for 30 min at 4˚C. Cells were washed 3 times and
lysed in 0.5 ml RIPA buffer containing leupeptin and aprotinin
(1 μg/ml). The extracts were centrifuged to remove insoluble
material. Protein contents were determined using the BCA
method. Equal amounts of protein (0.5 mg) for each
experimental sample were incubated overnight at 4˚C with
the specific antibodies (mouse anti-·vß3, 2 μl; and rabbit
anti-mouse, 10 μl). The antibody-integrin complexes were
incubated for another 1 h with protein A-Sepharose
(Pharmacia, Uppsala, Sweden), washed 3 times in RIPA
buffer and 3 times in purified water. Proteins were separated
by 6% SDS-PAGE, electrotransferred to nitrocellulose,
incubated with peroxidase-conjugated streptavidin and
visualized by chemiluminescence (SuperSignal Chemilu-
minescence Detection System, Pierce Biotechnology Inc.).
The experiment has been repeated 3 times.
Results
Leuprolide reduces the migratory and the invasive behavior
of DU 145 cells. Preliminary experiments were performed to
verify whether Leuprolide might affect the growth of
androgen-independent DU 145 prostate cancer cells, as
previously reported in our laboratory for other GnRH agonists
(24). We were able to confirm that Leuprolide exerts a dose-
dependent inhibitory effect on DU 145 cell proliferation, being
significantly effective in the range of doses 10-8-10-6 M
(Fig. 1A). On the basis of these results, the dose of 10-6 M
was selected for all subsequent experiments. This dose
corresponds to that of another GnRH agonist (Zoladex)
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Figure 1. Effects of Leuprolide on DU 145 cell proliferation (A), migration
(B), and invasion (C). (A) DU 145 cells, grown in serum-supplemented
medium, were treated for 7 days with Leuprolide (10-6 M). Cells were then
harvested and counted by hemocytometer. Data are expressed as mean cell
number ± SE (B) DU 145 cells, grown in serum-supplemented medium,
were treated for 4 days with Leuprolide (10-6 M) and then seeded in the
upper compartment of a Boyden's chamber for the haptotactic assay. Data
are expressed as mean number of migrated cells/mm2 ± SE. (C) DU 145 cells
were grown as aggregates in Matrigel covered with serum-supplemented
medium containing Leuprolide (10-6 M). Phase-contrast pictures of the
aggregates were taken after 4 and 9 days. Results from 1 out of 3 experiments
performed, are reported. Lane 1, aggregates in serum-starved medium; lane 2,
aggregates in serum-supplemented medium; lane 3, aggregates in serum-
supplemented medium, in the presence of Leuprolide. *p<0.05 vs. C, controls;
scale bar, 400 μm.
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previously utilized in our laboratory to investigate the mech-
anisms of the antiproliferative action of GnRH agonists on
DU 145 cells (10). These data are also in agreement with
those previously reported with Leuprolide on other prostate
cancer cell lines, both androgen-dependent and androgen-
independent (23,31). Similarly, Sica and coworkers have
demonstrated that Leuprolide counteracts the mitogenic
activity of EGF on androgen-independent PC3 prostate cancer
cells (32).
The effects of Leuprolide on the ability of prostate cancer
cells to migrate towards an extracellular matrix ligand
(vitronectin, 50 μg/ml) was investigated by means of a hapto-
tactic assay. We observed that, when DU 145 cells (grown in
serum-supplemented medium) were pretreated with Leuprolide
for 4 days before being seeded in a vitronectin-coated Boyden's
chamber, the number of the cells that migrated towards
vitronectin was significantly decreased when compared to
control cells (Fig. 1B).
Experiments were then performed to verify whether
Leuprolide might also affect the invasive behavior of androgen-
independent prostate cancer cells. The effects of Leuprolide
were evaluated on the ability of DU 145 cells to invade a
matrix of reconstituted basement membrane (Matrigel). DU
145 cells spontaneously form aggregates in Matrigel, when
prepared by the hanging-drop technique. Fig. 1C (lane 2)
shows that DU 145 cells, in serum-supplemented medium,
spontaneously leave the aggregates and invade the Matrigel
preparation at 4 and 9 days. Treatment of the cells with
Leuprolide completely abrogated their migration at the two
time intervals considered (Fig. 1C, lane 3).
Leuprolide inhibits the expression and the tyrosine-
phosphorylation of IGF-IR. We have previously shown that,
in DU 145 prostate cancer cells, the GnRH agonist Zoladex
reduces the concentration of IGF-IR as measured by radio-
receptor assay as well as the IGF-I-induced phosphorylation
of the IGF-IR (10). Experiments were now performed to
clarify whether similar effects might be elicited by Leuprolide.
By Western blot analysis, we demonstrated that treatment of
DU 145 cells with Leuprolide (10-6 M) substantially reduced
the expression of the IGF-IR protein (Fig. 2A). To evaluate
whether Leuprolide might also interfere with the phosphory-
lation of the IGF-IR, DU 145 cells were treated with the GnRH
agonist for either 1 or 2 h before being exposed to a 3-min
stimulus with IGF-I (10 nM) (10). Fig. 2B (lane 1) shows
that the IGF-I receptor is not phosphorylated in DU 145 cells
cultured in the absence of serum; this indicates that, in basal
conditions, the autocrine IGF-I is not sufficient to activate its
own receptors. As expected, IGF-I induced the phosphory-
lation of IGF-IR (Fig. 2B, lane 2). Leuprolide, when given
alone, was completely devoid of effect (Fig. 2B, lanes 3 and
4 vs. lane 1), a result which was expected since in basal
conditions IGF-IR was not activated (lane 1). The pre-
treatment of DU 145 cells with Leuprolide for 1 or 2 h
substantially counteracted the IGF-I-dependent phos-
phorylation of IGF-IR (Fig. 2B, lanes 5 and 6). These results
confirm that Leuprolide interferes with the IGF-I system
(receptor levels and phosphorylation), as previously
described for the other GnRH agonist Zoladex (10).
Leuprolide inhibits Akt phosphorylation induced by IGF-I.
We have recently reported that, in DU 145 cells, IGF-I exerts
its pro-migratory activity through the PI3-K/Akt signaling
pathway (20). Experiments were performed to verify whether
Leuprolide might interfere with the phosphorylation of the
Akt kinase induced by IGF-I. DU 145 cells, in serum-free
medium, were treated with Leuprolide (10-6 M) for 1 or 2 h,
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Figure 2. Effects of Leuprolide on IGF-IR expression (A) and IGF-IR
tyrosine-phosphorylation (B). (A) DU 145 cells, grown in serum-supplemented
medium, were treated with Leuprolide (10-6 M, 24 h). Western blotting of
IGF-IR was then performed. Results from 1 out of 3 experiments performed,
are reported. Lane 1, controls; lane 2, Leuprolide. (B) DU 145 cells, grown
in serum-starved medium, were treated with Leuprolide (10-6 M, 1 or 2 h)
before treatment with IGF-I (10 nM, 3 min). Lane 1, untreated controls;
lane 2, IGF-I; lane 3, Leuprolide (1 h); lane 4, Leuprolide (2 h); lane 5,
Leuprolide (1 h) + IGF-I; lane 6, Leuprolide (2 h) + IGF-I. Results from 1
out of 3 experiments performed, are reported.
Figure 3. Effects of Leuprolide on the Akt phosphorylation induced by IGF-I.
Starved DU 145 cells were treated with Leuprolide (10-6 M) for 1 or 2 h,
either in the absence or in the presence of IGF-I (10 nM) during the last
30 min of incubation. Lane 1, controls; lane 2, IGF-I (30 min); lane 3,
Leuprolide (1 h); lane 4, Leuprolide (2 h); lane 5, Leuprolide (1 h) + IGF-I
(30 min); lane 6, Leuprolide (2 h) + IGF-I (30 min). Western blot analysis was
then performed using specific antibodies against P-Akt (upper panel) or Akt
(lower panel). Results from 1 out of 3 experiments performed, are reported.
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either in the absence or in the presence of IGF-I (10 nM)
during the last 30 min of incubation. The level of Akt
phosphorylation was determined by Western blot analysis
using a phospho-Akt specific antibody. Fig. 3 (lane 1) shows
that, in basal conditions, DU 145 cells express undetectable
levels of phosphorylated Akt, confirming that, in the absence of
serum, autocrine IGF-I is not sufficient to activate its receptor
and the downstream signaling pathway. IGF-I induced a
significant increase of phosphorylation of the protein (Fig. 3,
lane 2), while Leuprolide was completely devoid of effect when
given alone (Fig. 3, lanes 3 and 4 vs. lane 1). Pretreatment
of the cells with the GnRH agonist substantially counteracted
the IGF-I-dependent phosphorylation of Akt at both time
intervals considered (Fig 3, lanes 5 and 6). These effects were
specific since the level of expression of the unphosphorylated
protein was found to be constant throughout the experiments
(Fig. 3).
Leuprolide counteracts the pro-migratory activity of IGF-I.
We have recently shown that IGF-I (10 nM) stimulates the
migration of DU 145 cells, and that this effect is accompanied
by a rearrangement of the cytoskeleton components as well
as by a change in cell morphology (as revealed by scanning
electron microscopy) and in integrin expression (20). Experi-
ments were then performed to clarify whether Leuprolide
(10-6 M) might decrease the migratory properties of prostate
cancer cells by interfering with the activity of IGF-I. DU 145
cells were treated with Leuprolide for 4 days, either alone or
in the presence of IGF-I during the last 24 h of treatment. Cells
were then seeded in the upper compartment of a Boyden's
chamber for the haptotactic assay. As expected, IGF-I
significantly promoted the migration of DU 145 cells (in
serum-free conditions) towards vitronectin. Leuprolide, when
given alone, did not affect cell migration; on the other hand,
the GnRH agonist significantly prevented the pro-migratory
effect of IGF-I (Fig. 4A). Similar results were obtained with
the androgen-independent prostate cancer cell line PC3
(Fig. 4B).
Leuprolide counteracts the pro-invasive activity of IGF-I.
Grzmil and coworkers (19) have recently reported that IGF-I
increases the invasive behavior of androgen-independent
PC3 prostate cancer cells. Experiments were performed to
verify whether Leuprolide might counteract the pro-invasive
activity of IGF-I on DU 145 cells. Using the Matrigel invasion
chamber, we found that IGF-I significantly increased the
ability of the cells to invade the Matrigel preparation and to
migrate towards the lower surface of the inserts. Leuprolide,
given alone, had no effect; however, the GnRH agonist
completely counteracted the pro-invasive activity of IGF-I
(Fig. 5, upper and lower panels).
Effects of Leuprolide on IGF-I-modulated cell morphology,
cytoskeleton organization and ·vß3 integrin expression. The
metastatic behavior of tumor cells is usually associated with
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Figure 4. Effects of Leuprolide on the pro-migratory activity of IGF-I.
Serum-starved DU 145 (A) and PC3 (B) cells were treated with Leuprolide
(10-6 M, 4 days), either alone or in the presence of IGF-I (10 nM) during the
last 24 h. Cells were then harvested, resuspended in their experimental
media, and seeded in the upper compartment of a Boyden's chamber for the
haptotactic assay. Data are expressed as the mean number of migrated
cells/mm2 ± SE. *p<0.05 vs. C, controls; **p<0.05 vs. IGF-I.
Figure 5. Effects of Leuprolide on the pro-invasive activity of IGF-I. Serum-
starved DU 145 cells were treated with Leuprolide (10-6 M, 4 days), either
alone or in the presence of IGF-I (10 nM) during the last 24 h. Cells were
then seeded in the upper compartment of a Matrigel invasion chamber. After
72 h, cells that had invaded the Matrigel preparation were fixed, stained and
counted. Upper panel, staining of cells migrated through the Matrigel
preparation. Lower panel, statistical evaluation of the results obtained. Data
are expressed as the mean cell number of invaded cells/mm2 ± SE. *p<0.05
vs. C, controls; **p<0.05 vs. IGF-I.
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changes in cell morphology, rearrangements of cytoskeletal
proteins, as well as alterations of the expression of cell
adhesion molecules, such as integrins. Scanning electron
microscopy was performed on DU 145 cells treated with IGF-I
and Leuprolide, either alone or in combination. Fig. 6B shows
the formation of lamellipodia in IGF-I-treated cells, which
are not present in control cells; the macrograph also shows
that the bodies of IGF-I-treated cells did not adhere to the
substratum. Leuprolide, alone, did not modify cell morphology
(Fig. 6C); however, the GnRH agonist substantially antago-
nized the morfological changes induced by IGF-I (Fig. 6D).
Immunofluorescence staining was then performed to
clarify whether Leuprolide might affect the IGF-I-induced
rearrangement of cytoskeletal components (actin and tubulin)
in prostate cancer cells. Fig. 7, confirming our previous
observations (20), shows that in DU 145 cells, IGF-I induced
a change of cell morphology, with acquisition of lamellipodia-
like protrusions and a redistribution of the actin cytoskeleton
as shown by an increased intensity of the fluorescence in
peripheral areas and at the leading edge of the protrusions.
Leuprolide, when given alone, did not exert any effect. DU 145
cells treated with the GnRH agonist exhibited a morphology
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Figure 6. Scanning electron microscopy of serum-starved DU 145 cells, treated with IGF-I (10 nM) and Leuprolide (10-6 M), either alone or in combination,
for 30 min. (A) Untreated controls; (B) IGF-I; (C) Leuprolide; (D) IGF-I + Leuprolide. Results from 1 out of 2 experiments performed, are reported. The IGF-I-
induced formation and extension of lamellipodia is counteracted by the GnRH agonist. Scale bar, 10 μm.
Figure 7. Immunofluorescence staining of F-actin and tubulin showing the effects of IGF-I (10 nM) and Leuprolide (10-6 M), either alone or in combination
(for 30 min), on cytoskeleton organization of DU 145 cells. Results from 1 out of 3 experiments performed, are reported. IGF-I induces lamellipodia
formation and a redistribution of the actin cytoskeleton with increased intensity of the immunofluorescence in peripheral areas below the cell membrane and
along the leading edge of lamellipodia. These effects are counteracted by Leuprolide. Neither IGF-I nor Leuprolide, either alone or in combination, affected
tubulin immunofluorescence. Scale bar, 16 μm.
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and an actin cytoskeletal organization similar to that of
control cells (Fig. 7). Neither IGF-I nor Leuprolide, given
alone or in combination, modified immunofluorescence
staining for tubulin in DU 145 cells (Fig. 7).
We have recently reported that, in DU 145 cells, IGF-I
increases the expression of ·vß3 integrin as evaluated both by
immunofluorescence and biotinylation/immunoprecipitation
followed by Western blot analysis (20). Herein, we studied
whether Leuprolide might counteract the action of IGF-I.
First of all, Fig. 8A confirms that, in IGF-I-treated cells, the
staining of ·vß3 fluorescence is increased vs. controls (Fig. 8A,
lane 2 vs. lane 1), with a clear localization of the integrin at
the cell membrane. Leuprolide, given alone (Fig. 8A, lane 3),
did not affect either the intensity of the fluorescence or the
cellular localization of ·vß3. On the other hand, the effect of
IGF-I was clearly abolished by the co-treatment of the cells
with the GnRH agonist (Fig. 8A, lane 4 vs. lane 2).
These observations were further confirmed at the protein
level. By biotinylation, immunoprecipitation and Western
blotting (Fig. 8B) we were able to show that, as expected,
·vß3 protein levels increased after IGF-I treatment (Fig. 8B,
lane 2). Leuprolide, given alone, did not affect integrin
expression (Fig. 8B, lane 3); however, the GnRH agonist
substantially antagonized the effect of the growth factor
(Fig. 8B, lane 4).
Discussion
In this study, we have shown that the GnRH agonist Leuprolide
reduces both the motility and the invasive behavior of
androgen-independent prostate cancer cells. To investigate
the possible mechanisms of this anti-metastatic action, we
first analyzed whether the GnRH agonist might interefere with
the activity of the growth factor IGF-I.
In a recent study, we have shown that IGF-I, through the
activation of its specific receptor, exerts a significant pro-
migratory activity on androgen-independent prostate cancer
cells (DU 145 and PC3); this effect is mediated by the PI3-K/
Akt signaling pathway (20). Moreover, the pro-migratory
activity of IGF-I on DU 145 cells is accompanied by a change
in cell morphology (induction of lamellipodia) and in actin
cytoskeleton organization (20). IGF-I also acts by increasing
the expression/activity of the ·vß3 integrin dimer (20), an
integrin whose expression has previously been demonstrated
to correlate with the aggressiveness and invasiveness of
prostate cancer cells (28). The observation that IGF-I promotes
the metastatic ability of androgen-independent prostate
cancer cells is also underlined by Grzmil and coworkers (19)
who have shown that IGF-I increases the invasive activity of
PC3 cells.
In the present study, we have demonstrated that, in
androgen-independent prostate cancer cells, Leuprolide
reduces both the expression and the tyrosine phosphorylation
of the IGF-I receptor, as previously shown for other GnRH
agonists (10); in these cells, Leuprolide also substantially
counteracts the IGF-I-induced phosphorylation of the Akt
kinase. These data indicate that, in androgen-independent
prostate cancer cells, GnRH agonists interfere with the IGF-I
system in terms of both IGF-IR expression and activation.
Moreover, we demonstrated that Leuprolide neutralizes the
pro-migratory and pro-invasive activity of IGF-I by counter-
acting the effects of this growth factor on cell morphology,
actin cytoskeleton organization and ·vß3 integrin expression.
It is clear from these results that, in DU 145 cells, GnRH
agonists may exert their anti-metastatic activity by eliciting
both very early events (IGF-IR phosphorylation, Akt
phosphorylation, changes of cell morphology, actin/integrin
intracellular redistribution) as well as events that require a
longer time before appearing (IGF-IR expression, changes in
cell motility/invasion, integrin expression). Since the
appearance of the early events elicited by Leuprolide only
needs changes in the activity of specific pre-existing proteins,
we believe that these events are likely mediated by the
activation of the G·i-cAMP signal transduction pathway
which also facilitates the translocation to the plasma
membrane of a protein phosphatase (33-35). On the other
hand, a longer time, and consequently a prolonged treatment
with the GnRH agonist, might be required in order to induce
more complex events, such as proliferation/migration/
invasion, which obviously require de novo protein synthesis.
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Figure 8. Effects of Leuprolide on the changes of ·vß3 integrin expression
induced by IGF-I. Lane 1, controls; lane 2, IGF-I (10 nM); lane 3, Leuprolide
(10-6 M); lane 4, IGF-I + Leuprolide; lane 5, negative controls (no primary
antibody). (A) Serum-starved DU 145 cells were treated with IGF-I and
Leuprolide, either alone or in combination for 30 min. Immunofluorescence
analysis of ·vß3 was then performed. Scale bar, 16 μm. (B) Serum-starved
DU 145 cells were treated with IGF-I and Leuprolide, either alone or in
combination for 24 h. Biotinylation, immunoprecipitation and Western
blotting of ·vß3 integrin was then performed. Results from 1 out of 3
experiments performed, are reported. (C) Densitometric analysis of ·vß3
integrin expression reported in (B). The results are expressed as a percentage
of the value of IGF-I-induced ·vß3 integrin levels and are the mean ± SE of
3 separate experiments.
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In line with the data reported herein, Gnanapragasam and
coworkers (36) have shown that the GnRH agonist Buserelin
substantially counteracts the pro-invasive effects of the
fibroblast growth factor (FGF) on DU 145 cells. Moreover,
Dondi and coworkers (31) have reported that Leuprolide
exerts an anti-metastatic activity on androgen-independent
prostate cancer cells, through the inhibition of the urokinse
plasminogen activator (uPA) system.
However, the results seem to diverge, at least partially,
from those recently published by Enomoto et al (37). These
authors have studied the effects of GnRH and of the second
form of GnRH recently found in mammals (GnRH-II) (38-
41) on the motility of two prostate cancer cell lines (TSU-Pr1
and DU 145), by utilizing a modified Boyden's chamber. They
have reported that GnRH does not affect the migration of
either TSU-Pr1 or DU 145 cells when the peptide is placed in
the lower compartment of the chamber as a chemo-attractant.
On the other hand, the addition of GnRH to the cells in the
upper compartment appears able to modulate cell migration
(inhibiting it in DU 145 cells, and, on the contrary, being
stimulatory in TSU-Pr1 cells) when the conditioned medium
of the same cell line is placed in the lower compartment.
Similar results have been reported by these authors for GnRH-
II. The reasons for the discrepancy between the data by
Enomoto and coworkers (37) and those reported in the
present study probably reside in the many differences
encountered in the methodology applied. First of all, the
migration assay, based on the Boyden's chamber technique,
has been developed in different experimental conditions. In
our studies, the ability of the GnRH agonist to affect cell
motility has been evaluated by means of a haptotactic assay,
using vitronectin as the chemoattractant. Enomoto and
coworkers, in their first series of experiments, used an assay
where GnRH and GnRH-II, placed in the lower compartment
of the chamber, would act as the chemoattractant. In a
subsequent experiment, GnRHs were able to affect the
motility of the cells (in opposite fashions) when added in the
upper compartment of the chamber and when the conditioned
media of the same cells were placed as chemoattractants in
the lower compartment. A more important difference resides
in the fact that Enomoto and coworkers used native GnRHs
rather than GnRH analogs. It is known that the half-life of
GnRHs is very short (in the range of minutes) and,
consequently, it is expected that very little, if any, GnRHs
might be present at the end of the experiment (hours). This
obviously does not happen with GnRH analogs. Finally, we
have shown that Leuprolide decreases the migration of both
DU 145 and PC3 cell lines, which are well studied and are
usually considered the best example of androgen-independent
cells. On the other hand, Enomoto and coworkers, while
confirming an anti-migratory activity of GnRHs on DU 145
cells which is comparable to that presented herein, reported
an opposite effect of the peptides on the TSU-Pr1 cell line,
which is another experimental model of androgen-independent
prostate carcinoma. These authors speculate that the opposite
effects of GnRH on the migration of TSU-Pr1 and DU 145
cells are linked to different types of GnRH receptors which
might be present on the two cell lines.
In support to our observations, an anti-metastatic
activity for GnRH agonists has been previously reported also
for cancers not related to the reproductive system, such as
melanoma (42) and epidermoid carcinoma (43), expressing
the GnRH receptor. Moreover, GnRH agonists have been
consistently shown to be inhibitory on the proliferation of
both hormone-related (breast,  endometrium, ovary,
prostate) (34,44-49) and hormone-unrelated cancer cells
(42,43).
The results shown in the present study, such as those by
Gnanapragasam and coworkers (36) indicate that GnRH
agonists inhibit the metastatic behavior of prostate cancer cells,
at least partially, by interfering with the stimulatory action of
growth factors. This conclusion also seems to be supported
by Yates and coworkers (50), who reported that the GnRH
antagonist Cetrorelix reduces the invasive profile of DU 145
cells engineered to overexpress the epidermal growth factor
(EGF) receptor. To this purpose, it must be noted that
Cetrorelix behaves as an antagonist at the GnRH receptor on
pituitary gonadotropes and as an agonist at the same receptor
on cancer cells (51-55).
In a previous study, we have shown that GnRH agonists
reduce the growth of DU 145 cells by interfering with the
mitogenic activity of the IGF-I system; these compounds act,
as reported also in this study, by decreasing the concentration
of IGF-I binding sites and by counteracting the tyrosine phos-
phorylation of these receptors induced by IGF-I (10). These
observations, taken together with those presented in this study,
indicate that, in androgen-independent prostate cancer cells,
GnRH agonists might exert a direct antitumor effect (by
reducing both the proliferation and the metastatic behavior of
the cells) acting, at least partially, by interfering with the
activity of the growth factor IGF-I.
As it is very well known, GnRH agonists are widely and
successfully used for the treatment of androgen-dependent
prostate carcinoma, on the basis of their ability to suppress the
function of the pituitary-gonadal axis (2). The present data
strongly suggest that these compounds might be considered
also as a possible treatment for the most advanced hormone-
resistant prostate carcinoma. Also the recent study by
Gnanapragasam et al (36), based on clinical observations,
supports this hypothesis. In this study, prostate cancer patients
expressing high levels of GnRH receptors in the tumoral
tissue, were divided into two groups of treatments: GnRH
agonist therapy or surgical castration. The authors report that
patients who received GnRH agonists had a longer survival
than those who were surgically castrated. The authors
propose an interesting hypothesis to explain the direct
antitumor activity exerted by GnRH agonists in prostate
cancer. According to this hypothesis, the direct antitumor
activity of these compounds might not be apparent in the
androgen-dependent phase of the pathology since this is
masqued by the indirect inhibition induced by the
suppression of testosterone secretion. On the contrary, in
androgen-independent prostate cancers which express high
levels of GnRH receptors, GnRH agonists may exert their
‘pure’ direct anti-mitogenic and anti-metastatic activities
which will be associated with a prolongation of the life of the
patient.
A general practical conclusion which may be derived
from the present study is that the level of expression of GnRH
receptors in prostate cancers might represent a novel molecular
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marker able to help in deciding whether the treatment with
GnRH analogs might be useful also in the more advanced
phase of pathology.
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